Outlook Therapeutics Operating Expenses Growth & History (OTLK)
Outlook Therapeutics's operating expenses was $67.1M for fiscal 2025.
View full Outlook Therapeutics company overviewOutlook Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $67.1M | −$4.6M | −6.39% |
| 2024 | 2024-09-30 | $71.7M | $18.6M | +34.97% |
| 2023 | 2023-09-30 | $53.1M | −$9.9M | −15.77% |
| 2022 | 2022-09-30 | $63.1M | $11.3M | +21.93% |
| 2021 | 2021-09-30 | $51.7M | $14.9M | +40.41% |
| 2020 | 2020-09-30 | $36.8M | −$7.6M | −17.11% |
| 2019 | 2019-09-30 | $44.4M | $11.7M | +35.79% |
| 2018 | 2018-09-30 | $32.7M | −$7.0M | −17.53% |
| 2017 | 2017-09-30 | $39.7M | −$14.6M | −26.94% |
| 2016 | 2016-09-30 | $54.3M | $2.5M | +4.91% |
| 2015 | 2015-09-30 | $51.8M | — | — |
Outlook Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $10.8M | −$6.0M | −35.76% |
| Q2 2026 | 2026-03-31 | $14.0M | $1.6M | +13.02% |
| Q1 2026 | 2025-12-31 | $12.2M | — | — |
| Q4 2025 | 2025-09-30 | $16.3M | — | — |
| Q3 2025 | 2025-06-30 | $16.8M | −$2.7M | −14.05% |
| Q2 2025 | 2025-03-31 | $12.4M | −$6.5M | −34.57% |
| Q3 2024 | 2024-06-30 | $19.6M | $1.4M | +7.83% |
| Q2 2024 | 2024-03-31 | $18.9M | $12.1M | +176.98% |
| Q3 2023 | 2023-06-30 | $18.1M | — | — |
| Q2 2023 | 2023-03-31 | $6.8M | — | — |
| Q4 2021 | 2021-09-30 | $13.4M | $3.4M | +34.17% |
| Q3 2021 | 2021-06-30 | $11.5M | −$404,182 | −3.40% |
| Q2 2021 | 2021-03-31 | $12.6M | $5.9M | +86.66% |
| Q1 2021 | 2020-12-31 | $14.2M | $6.0M | +73.40% |
| Q4 2020 | 2020-09-30 | $10.0M | −$8.5M | −46.00% |
| Q3 2020 | 2020-06-30 | $11.9M | $5.7M | +90.74% |
| Q2 2020 | 2020-03-31 | $6.8M | −$1.6M | −18.97% |
| Q1 2020 | 2019-12-31 | $8.2M | −$3.1M | −27.73% |
| Q4 2019 | 2019-09-30 | $18.5M | $5.4M | +40.65% |
| Q3 2019 | 2019-06-30 | $6.2M | −$1.8M | −22.07% |
| Q2 2019 | 2019-03-31 | $8.3M | $743,886 | +9.78% |
| Q1 2019 | 2018-12-31 | $11.3M | $7.4M | +186.59% |
| Q4 2018 | 2018-09-30 | $13.2M | $7.4M | +126.84% |
| Q3 2018 | 2018-06-30 | $8.0M | $352,232 | +4.61% |
| Q2 2018 | 2018-03-31 | $7.6M | −$538,241 | −6.61% |
| Q1 2018 | 2017-12-31 | $4.0M | −$14.1M | −78.17% |
| Q4 2017 | 2017-09-30 | $5.8M | −$4.6M | −44.36% |
| Q3 2017 | 2017-06-30 | $7.6M | −$14.9M | −66.08% |
| Q2 2017 | 2017-03-31 | $8.1M | $4.2M | +106.17% |
| Q1 2017 | 2016-12-31 | $18.1M | $690,251 | +3.97% |
| Q4 2016 | 2016-09-30 | $10.4M | — | — |
| Q3 2016 | 2016-06-30 | $22.5M | $10.2M | +82.51% |
| Q2 2016 | 2016-03-31 | $3.9M | −$10.5M | −72.76% |
| Q1 2016 | 2015-12-31 | $17.4M | — | — |
| Q3 2015 | 2015-06-30 | $12.3M | — | — |
| Q2 2015 | 2015-03-31 | $14.5M | — | — |
Outlook Therapeutics operating expenses trends
Over the last five fiscal years, Outlook Therapeutics's operating expenses increased from $36.8M to $67.1M, a change of $30.3M. The latest reported quarter, Q3 2026, shows $10.8M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Outlook Therapeutics source filings ↗